What roles did Dr Paul Cox hold at Neurocept and when did he join the company?

1. Who the supplied reporting actually profiles: Paul Alan Cox, ethnobotanist and Brain Chemistry Labs director

The largest cluster of documents in the set describe Paul Alan Cox, an ethnobotanist with a long academic and conservation record who is presented as Executive Director of Brain Chemistry Labs and the public face of a small Jackson Hole research effort focused on neurodegenerative “tangle” diseases, with profiles and news posts that repeatedly identify him in that role ^{[1] [2] [3] [5]}. Those sources record his academic pedigree and awards and recount his leadership of Brain Chemistry Labs and related public appearances, including interviews and symposiums, which positions him as the likely subject when articles discuss a “Dr. Paul Cox” working on Alzheimer’s research in Jackson Hole ^{[1] [2] [3] [5]}.

2. A second Dr. Paul Cox in the results is a practicing psychiatrist, not a biotech executive

A separate set of entries refers to Paul D. Cox, M.D., a board‑certified psychiatrist in Davis, California, with profiles on Doximity, Psychology Today, and physician directories that document his medical training and clinical roles rather than corporate or biotech affiliations ^{[4] [6] [7]}. Those listings demonstrate that at least two distinct professionals named Paul Cox appear in the public record provided here, increasing the risk of conflating identities if one searches for corporate roles without precise identifiers ^{[4] [6] [7]}.

3. The supplied sources contain no mention of Neurocept, its board, or a hire date for any Dr. Paul Cox

A targeted review of the material supplied reveals detailed biographical and institutional references for Brain Chemistry Labs and for Paul D. Cox’s clinical practice but no references to Neurocept, no corporate biographies tying either Paul Cox to Neurocept, and no dates of employment or titles at a company by that name in these documents ^{[1] [2] [3] [4]}. Because the dataset lacks any Neurocept mentions, any definitive statement about roles or joining dates at Neurocept would require additional sources beyond those provided ^{[1] [2] [3] [4]}.

4. How identity confusion and reporting focus can produce apparent contradictions

The materials illustrate how reporting that centers on a prominent “Dr. Paul Cox” in Alzheimer’s work (Paul Alan Cox) alongside separate clinical profiles for a different Paul Cox (the psychiatrist) can create ambiguity when an external question asks about corporate roles at Neurocept; such ambiguities often arise when multiple public figures share a common name and when summaries omit corporate affiliations, as is the case in the supplied pages ^{[1] [2] [4] [3]}. The Fortune profile and Brain Chemistry Labs pages emphasize small‑lab, non‑industry research and executive leadership at Brain Chemistry Labs rather than any biotech‑company employment, which further suggests the absence of Neurocept linkage in these sources ^{[3] [2]}.

5. What can be done next to get the factual answer sought

To definitively determine whether a Dr. Paul Cox held roles at Neurocept and when he joined, the necessary next steps are to consult sources that explicitly document corporate affiliations: Neurocept’s press releases and SEC or company filings, corporate leadership pages, LinkedIn and other professional profiles for people named Paul Cox, and trade coverage that profiles Neurocept executives — none of which are present in the supplied reporting and therefore must be consulted to answer the question authoritatively ^{[1] [2] [3] [4]}. Until those records are produced, any claim about roles or join dates at Neurocept would be unsupported by the current documents and should be treated as unverified.